Evaluation of the combined effect of aripiprazole and sertraline in the treatment of obsessive-compulsive disorder in adolescents

Assarian, Fatemeh; Safaei,  Reza; Ghoreishi, Fatemeh Sadat; Rahimi, Habibollah

doi:10.48307/FMSJ.2024.28.6.631

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Basic and Clinical Biochemistry and Nutrition

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 28, Issue 6 (Bimonthly 2024)

Feyz Med Sci J 2024, 28(6): 631-638

Back to browse issues page

Evaluation of the combined effect of aripiprazole and sertraline in the treatment of obsessive-compulsive disorder in adolescents

Fatemeh Assarian

, Reza Safaei

, Fatemeh Sadat Ghoreishi

, Habibollah Rahimi ^*

Department of Epidemiology and Biostatistics, Faculty of Health, Kashan University of Medical Sciences, Kashan, Iran

Abstract: (311 Views)

Background and Aim: Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric condition affecting 2-4% of adolescents. Due to the high prevalence of this disorder and the limited, sometimes contradictory studies on its treatment, especially in resistant cases, this research aimed to assess the combined effect of aripiprazole and sertraline and compare it with the effect of sertraline alone.
Methods: This double-blind clinical trial was conducted on adolescents diagnosed with OCD who attended psychiatric clinics in Kashan. Diagnosis was based on the clinical assessment of a psychiatrist and DSM criteria. The study lasted for 12 weeks, with patients randomly assigned to one of the treatment groups using block randomization. The Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) for children and adolescents was administered to all patients at baseline, and at weeks 4, 8, and 12. Treatment response was evaluated by the change in Y-BOCS scores from baseline to the end of the study and by comparing the two treatment groups.
Results: The study involved 40 patients (20 per group). The mean age in the aripiprazole + sertraline group was 14.75 ± 1.29 years, and in the sertraline-only group was 15.10 ± 1.59 years. Both groups were homogeneous in terms of age and gender. Repeated measures ANOVA revealed a significant reduction in total Y-BOCS scores in both groups (P<0.001, F=193.53). Additionally, the rate of score reduction over time was greater in the intervention group (aripiprazole + sertraline) (P<0.001, F=37.92). However, no significant difference was found between the two groups in final Y-BOCS scores (P=0.17, F=1.94), indicating similar effects of both treatments. The results for obsessive thoughts followed a similar pattern, while a significant difference was observed between the two groups for compulsive behaviors.
Conclusion: Adding aripiprazole to sertraline in the treatment of adolescent OCD significantly improved the reduction of compulsive behaviors. However, no significant difference in the reduction of obsessive thoughts was found between the combined treatment and sertraline alone.

Keywords: Obsessive-compulsive disorder, Aripiprazole, Sertraline, Adolescents

Full-Text [PDF 449 kb] (73 Downloads)

Type of Study: Research | Subject: General
Received: 2024/11/2 | Revised: 2025/02/5 | Accepted: 2025/01/12 | Published: 2025/02/5

References

1. Rabert B Marcial. V. Kaplan & Sadock's Comprehensive TextBook of Psychiatry.11th ed.Wolters Kluwer; 2025. P.12477.

2. Sadock BJ, Sadock VA. Synopsis Of Psychiatry.12th ed. Philadelphia: Lippincott Williams & Wilkins; 2022. p. 206.

3. Dulcan MK, editor. Dulcan's textbook of child and adolescent psychiatry. American Psychiatric Pub; 2021 Oct 18. doi:10.1176/appi.books.9781615374809 PMid:33818599 PMCid:PMC8022269

4. Assarian F, Biqam H, Asqarnejad A. An epidemiological study of obsessivecompulsive disorder among high school students and its relationship with religious attitudes. Arch Iran Med. 2006;9(2):104-7

5. Dold M, Aigner M, Lanzenberger R, Kasper S. Efficacy of antipsychotic augmentation therapy in treatment resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr Neurol Psychiatr. 2011; 79(8): 453-66. doi:10.1055/s-0031-1273397 PMid:21809258

6. Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, et al. N-Acetylcysteine Add-On Treatment in Refractory Obsessive-Compulsive Disorder A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychopharmacol 2012; 32: 797-803. doi:10.1097/JCP.0b013e318272677d PMid:23131885

7. Carey PD, Lochner C, Kidd M, Ameringend MV, Steinc DJ, Denys D. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable? Int Clin Psychopharmacol. 2012; 27(6): 321-5. doi:10.1097/YIC.0b013e3283576881 PMid:22859064

8. Ardic UA, Ercan ES, Kutlu A, Yuce D, Ipci M, Inci SB. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood. Child Psychiatry Hum Dev. 2016: 1-6.

9. Ercan ES, Ardic UA, Ercan E, Yuce D, Durak S. A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015; 25(7): 580-4. doi:10.1089/cap.2014.0128 PMid:26375768

10. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor refractory obsessive compulsive disorder: a single blind, randomised study. Human Psychopharmacology: Clin Experimental. 2011; 26(1): 51-7. doi:10.1002/hup.1169 PMid:21308781

11. Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010; 30(6): 688-93 doi:10.1097/JCP.0b013e3181fab7b1 PMid:21105283

12. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, et al. Children's Yale-Brown obsessive compulsive scale: reliability and validity. J Am Academy Child Adolescent Psychiatry. 1997; 36(6): 844-52. doi:10.1097/00004583-199706000-00023 PMid:9183141

13. Gallant J, Storch EA, Merlo LJ, Ricketts ED, Geffken GR, Goodman WK, et al. Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-symptom checklist. J Anxiety Disord. 2008; 22(8):1369-76. doi:10.1016/j.janxdis.2008.01.017 PMid:18329843

14. Mohsenabadi H, Shabani MJ, Assarian F, Zanjani Z. Psychometric Properties of the Child and Adolescent Mindfulness Measure: A Psychological Measure of Mindfulness in Youth. 2020; 14(1):e79986. doi:10.5812/ijpbs.79986

15. National Institute for Health and Clinical Excellence: guidance. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder, 2006.

16. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR, Connor KM. The use of aripiprazole in obsessive- compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005; 66(1): 49-51 doi:10.4088/JCP.v66n0107 PMid:15669888

17. Barkoulias V, Stockings E. Asystematic review of the use of risperidone paliperidone and aripiprazole as augmentating agents for obsessive compulsive disorder. Expert Opin Pharmacother. 2019; 20(1): 47-53. doi:10.1080/14656566.2018.1540590 PMid:30360669

18. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety. 2008; 25(2): 172-4. doi:10.1002/da.20303 PMid:17340610

19. Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2008; 197(4): 687-8. doi:10.1007/s00213-008-1091-1 PMid:18264798

20. Ercan ES, Ardic UA, Ercan E, Yuce D, Durak S. A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015; 25(7): 580-4. doi:10.1089/cap.2014.0128 PMid:26375768

21. Yaylaci F, Erkuran HO, Eyuboglu M. Early-term Aripiprazole Augmentation and Clinical Efficacy in Treatment of Pediatric OCD: A Case Series of Six Adolescents. Psychiatry Behav Sci. 2019; 9(4): 179.doi:10.5455/PBS.20190221072254

22. Efficacy in Treatment of Pediatric OCD: A Case Series of Six Adolescents. Psychiatry Behav Sci. 2019; 9(4): 179-87.

Add your comments about this article

‎ 10.48307/FMSJ.2024.28.6.631

Mendeley

Zotero

RefWorks

Assarian F, Safaei R, Ghoreishi F S, Rahimi H. Evaluation of the combined effect of aripiprazole and sertraline in the treatment of obsessive-compulsive disorder in adolescents. Feyz Med Sci J 2024; 28 (6) :631-638
URL: http://feyz.kaums.ac.ir/article-1-5255-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 28, Issue 6 (Bimonthly 2024)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4679